Has Jan Hoffman received payments from drug or device companies?

Yes. Drug and device makers reported $5,251 in general payments to Jan Hoffman across 230 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jan Hoffman did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jan Hoffman come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jan Hoffman

Endocrinology, Diabetes & Metabolism · Newton, KSNPI 1659308229

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 230 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,230 and has fallen 83.3% since, to $372 in 2025.

$5,251in general payments, 2019–2025

Across 230 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$1K
Lilly USA, LLC$936
AbbVie$493
Medtronic$473
AstraZeneca$303
Amgen$244
plus $2K from 14 others

What the payments were for

Food & beverage$5,21799%
Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	53	$1,166
Lilly USA, LLC	54	$936
AbbVie	37	$493
Medtronic(2 entities)	10	$473
AstraZeneca	11	$303
Amgen	4	$244
Amarin Pharma, Inc.	8	$228
Amneal Pharmaceuticals LLC	14	$210
Bayer	2	$208
Sanofi-aventis U.S. LLC	15	$207
Abbott	2	$167
Janssen Scientific Affairs, LLC	1	$125
Esperion Therapeutics, Inc.	1	$125
Radius Health, Inc.	1	$100
Boehringer Ingelheim	6	$97
Dexcom, Inc.	3	$55
Tandem Diabetes Care, Inc.	3	$43
Merck	2	$39
Johnson & Johnson	2	$19
GRT US Holding, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,251 in reported general payments places this provider in the 65th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.

See all endocrinology, diabetes & metabolism providers in Kansas →

Other endocrinology, diabetes & metabolism in Newton

Dany ZayourWichita$744K
Andrew GreenShawnee Mission$322K
Michael SokolOverland Park$227K
Rami MortadaWichita$105K
Sajeev MenonOverland Park$25K
Georges ElhomsyWichita$14K
Richard GomendozaSalina$13K
John MilesKansas City$13K
Nichole SmithMerriam$9K
Susan BrianTopeka$9K

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →